Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2009

View Archived Issues

AVI BioPharma reports efficacy data from phase Ib/II clinical trial of AVI-4658 in DMD

Forest Laboratories to acquire additional rights to NXL-104 under agreement with Novexel

Novel DNA-binding compounds presented by CSIR

GlaxoSmithKline describes nAChR modulators as antipsychotic agents

Mitsubishi Tanabe Pharma discloses novel BK and maxi K+ channel openers

Cathepsin C inhibitors for the treatment of COPD identified by GlaxoSmithKline

Lilly identifies CB1 ligands for the treatment of obesity

New data indicate ridaforolimus-trastuzumab beneficial in refractory metastatic breast cancer

Compugen discovers drug target for treatment of epithelial tumors

Sinovac Biotech files application with SFDA for clinical trial of HFMD vaccine

SemBioSys Genetics presents update of its progress on Apo AI(Milano)

Tego Biosciences sells intellectual property to Luna Innovations

BTC induces apoptosis in PKCalpha overexpressing breast cancer cells

Glycemic control enhanced by adding alogliptin to insulin therapy in type 2 diabetes

Breast cancer growth inhibition seen with JMR-132 and tamoxifen

MVA-BN-HER2 well tolerated, active in phase I breast cancer studies

Tetrathiomolybdate may reduce endothelial progenitor cells in breast cancer patients

EMEA issues negative opinion on Cerepro for malignant brain cancer

Affomix to provide antibodies for Kalgene's diagnostics program

LifeCycle submits phase III protocol for LCP-Tacro trial to the FDA

Vical's phase III trial of Allovectin-7 receives positive safety review

Vivus submits NDA for Qnexa to FDA for treatment of obesity

Arigene terminates tender offer for Trimeris' outstanding shares of common stock

GSK identifies 5-HT2B receptor antagonists for fibrotic conditions and IBS

Gilead describes SCD inhibitors for the treatment of obesity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...